CRISPR Therapeutics (NASDAQ:CRSP) PT Raised to $52.00

CRISPR Therapeutics (NASDAQ:CRSP) had its price target boosted by analysts at Robert W. Baird from $46.00 to $52.00 in a research report issued on Thursday, Benzinga reports. The firm presently has a “neutral” rating on the stock. Robert W. Baird’s target price points to a potential downside of 2.42% from the stock’s previous close.

Other equities analysts have also recently issued reports about the stock. Needham & Company LLC reiterated a “buy” rating and set a $90.00 target price on shares of CRISPR Therapeutics in a research note on Thursday, April 11th. TheStreet upgraded CRISPR Therapeutics from a “d+” rating to a “c” rating in a research note on Friday, February 23rd. Mizuho raised their price objective on CRISPR Therapeutics from $82.00 to $99.00 and gave the stock a “buy” rating in a research report on Wednesday, March 6th. Chardan Capital upped their target price on CRISPR Therapeutics from $110.00 to $112.00 and gave the company a “buy” rating in a research note on Thursday, February 22nd. Finally, Citigroup lifted their price target on shares of CRISPR Therapeutics from $88.00 to $89.00 and gave the stock a “buy” rating in a research note on Thursday, April 18th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $74.67.

CRISPR Therapeutics Price Performance

NASDAQ CRSP opened at $53.29 on Thursday. CRISPR Therapeutics has a fifty-two week low of $37.55 and a fifty-two week high of $91.10. The stock’s 50-day moving average is $65.81 and its two-hundred day moving average is $64.64. The firm has a market cap of $4.52 billion, a P/E ratio of -27.19 and a beta of 1.80.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its earnings results on Wednesday, February 21st. The company reported $1.10 earnings per share for the quarter, topping the consensus estimate of $0.15 by $0.95. The company had revenue of $201.20 million during the quarter, compared to analyst estimates of $148.72 million. During the same quarter last year, the firm posted ($1.41) earnings per share. The firm’s revenue for the quarter was up 3253.3% compared to the same quarter last year. On average, equities analysts expect that CRISPR Therapeutics will post -6.24 EPS for the current year.

Insider Transactions at CRISPR Therapeutics

In related news, General Counsel James R. Kasinger sold 1,913 shares of the company’s stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $79.67, for a total transaction of $152,408.71. Following the sale, the general counsel now owns 57,371 shares in the company, valued at approximately $4,570,747.57. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, General Counsel James R. Kasinger sold 1,913 shares of the business’s stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $79.67, for a total transaction of $152,408.71. Following the transaction, the general counsel now owns 57,371 shares in the company, valued at approximately $4,570,747.57. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, General Counsel James R. Kasinger sold 2,801 shares of the firm’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $78.26, for a total transaction of $219,206.26. Following the completion of the sale, the general counsel now owns 60,070 shares of the company’s stock, valued at $4,701,078.20. The disclosure for this sale can be found here. In the last ninety days, insiders sold 83,992 shares of company stock valued at $6,132,335. Corporate insiders own 4.10% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Interchange Capital Partners LLC lifted its holdings in shares of CRISPR Therapeutics by 7.6% in the 1st quarter. Interchange Capital Partners LLC now owns 7,125 shares of the company’s stock worth $489,000 after purchasing an additional 505 shares in the last quarter. Entropy Technologies LP acquired a new position in CRISPR Therapeutics during the first quarter worth $1,723,000. ProShare Advisors LLC lifted its stake in shares of CRISPR Therapeutics by 10.1% in the first quarter. ProShare Advisors LLC now owns 5,791 shares of the company’s stock valued at $395,000 after buying an additional 530 shares in the last quarter. Reynders McVeigh Capital Management LLC raised its holdings in shares of CRISPR Therapeutics by 5.4% in the 1st quarter. Reynders McVeigh Capital Management LLC now owns 96,979 shares of the company’s stock worth $6,611,000 after acquiring an additional 4,931 shares during the last quarter. Finally, Susquehanna Fundamental Investments LLC bought a new position in shares of CRISPR Therapeutics in the first quarter valued at approximately $1,602,000. Institutional investors own 69.20% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.